

(Registration Number: 200819599W)

UNAUDITED FINANCIAL UPDATE FOR NINE MONTHS ENDED 30 SEPTEMBER 2022

This Unaudited Financial Update is a voluntary disclosure of the Company's Income Statement, Statement of Comprehensive Income and Statement of Financial Position for nine months ended 30 September 2022. For a limited discussion of the Company's nine months ended 30 September 2022 financial results, please refer to the Company's Investor Presentation nine months ended 30 September 2022 Financial Results available on the SGXnet and the Company's website www.japfa.com.

(Registration Number: 200819599W)

Income statement (for the group) together with a comparative statement for the corresponding period of the immediately preceding financial year.

Income Statement

	Jan - Sep		
	2022 2021		Cha
	US\$'000	US\$'000	_
Revenue	3,738,323	3,383,670	1
Cost of sales	(3,155,239)	(2,765,409)	1
Gross profit	583,084	618,261	-
Marketing and distribution costs	(123,433)	(112,596)	1
Administrative expenses	(235,975)	(239,186)	
Operating profit	223,676	266,479	-1
Interest income	1,778	2,924	-3
Finance costs	(81,743)	(71,189)	1
Other gain	9,079	31,293	-7
Foreign exchange adjustments loss	(13,436)	(16,189)	-2
Changes in fair value of biological assets ¹	(1,866)	20,169	n
Share of results of associate and joint ventures	915	(70)	n
Profit before tax	138,403	233,417	-4
Tax expense	(30,154)	(39,213)	-2
Profit, net of tax	108,249	194,204	
Other comprehensive loss:			
Items that will not be reclassified to profit or loss:			
Remeasurement of the net defined benefits plan, net of tax	2,677	5,663	-5
tems that may be reclassified subsequently to profit or loss:			
Exchange differences on translating foreign operations, net of tax	(156,734)	(15,816)	89
Share of other comprehensive loss of associate and joint ventures	(1,533)	(290)	42
Cash flow hedges	(14,322)	(2,273)	_ 53
Other comprehensive loss for the year, net of tax	(169,912)	(12,716)	_ n
Total comprehensive (loss)/income	(61,663)	181,488	= n
Profit after tax attributable to owners of the parent, net of tax ("PATMI")	46,341	113,886	-[
Profit after tax attributable to non-controlling interests, net of tax	61,908	80,318	-2
Profit, net of tax	108,249	194,204	
Fotal comprehensive (loss)/income			
attributable to owners of parent, net of tax	(61,034)	103,911	n
otal comprehensive (loss)/income			
attributable to non-controlling interests, net of tax	(629)	77,577	n
Total comprehensive (loss)/income	(61,663)	181,488	_ n
Earnings per share for profit for the period attributable to owners of the para	ent during the yea	r:	
Basic and diluted (cents)	2.27	5.58	-! =

n/m : not meaningful

¹ Changes in Fair Value of Biological Assets in 9M 2022 includes the gain of US\$7.5 million (9M 2021: US\$15.3 million) arising from fattening beef that were sold in China during the period.

(Registration Number: 200819599W)

Income statement (for the group) together with a comparative statement for the corresponding period of the immediately preceding financial year. (cont'd)

Additional information:

Management believes that Core PATMI w/o forex and EBITDA are important measures of performance, although these are not standard measures under IFRS.

	Jan - S	Jan - Sep		
	2022 US\$'000	2021 US\$'000	Change %	
Core PATMI w/o forex	65,684	120,958	-46%	

We derived Core PATMI from "Profit Attributable to Owners of the Parent, Net of Tax" by excluding a) changes in fair value of biological assets (net of tax), other than gains/(losses) from the sale of beef in China¹, b) changes in fair value of derivatives, and c) extraordinary items, attributable to the owners of the parent.

Core PATMI w/o forex is an estimate derived from Core PATMI by excluding foreign exchange gains/losses (before tax) attributable to the owners of the parent. We have not made an estimate of the tax impact on foreign exchange gains/losses.

	Jan - S	Jan - Sep		
	2022 US\$'000	2021 US\$'000	Change %	
EBITDA	347,641	420,951	-17%	

We define EBITDA as profit before tax, excluding interest income, finance costs, depreciation and amortisation expenses. We also exclude a) foreign exchange adjustments gains/(losses), b) changes in fair value of derivatives relating to foreign exchange hedging, and c) fair value of biological assets, other than gains/(losses) from the sale of beef in China¹.

Net Profit is arrived at after (charging)/ crediting the following:

	Jan - Sep		
	2022	2021	Change
	US\$'000	US\$'000	%
Income /(expenses)			
Finance costs			
- Interest expense on loans and borrowings	(65,071)	(59,538)	9%
- Interest expense on lease liabilities	(16,672)	(11,651)	43%
Depreciation of property, plant and equipment	(79,248)	(92,414)	-14%
Depreciation of investment properties	(556)	(259)	115%
Depreciation of right-of-use assets	(25,501)	(21,477)	19%
Amortisation of intangible assets	(1,131)	(1,110)	2%
Changes in fair value of biological assets	(1,866)	20,169	n/m
Foreign exchange adjustments loss	(13,436)	(16,189)	-17%
Gain on derivative financial instruments			
- Forex	-	7,292	n/m
- Non-forex	-	329	n/m
Loss on disposal of property, plant and equipment			
and investment properties	(551)	(30)	n/m

n/m : not meaningful

¹ Changes in Fair Value of Biological Assets in 9M 2022 includes the gain of US\$7.5 million (9M 2021: US\$15.3 million) arising from fattening beef that were sold in China during the period.

(Registration Number: 200819599W)

Statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.

	Group		Com	pany
	As at 30/9/2022 US\$'000	As at 31/12/2021 US\$'000	As at 30/9/2022 US\$'000	As at 31/12/2021 US\$'000
ASSETS	033 000	033 000	033 000	033 000
Non-current assets				
Property, plant and equipment	1,359,292	1,341,657	85	99
Right-of-use assets	377,981	336,911	617	988
nvestment properties	23,756	25,874	-	
ntangible assets	13,665	14,543		_
nvestment in subsidiaries	13,005	14,545	923,107	908,735
nvestments in associate and joint ventures	37,258	34,368	28,000	28,000
Biological assets	530,290	511,998	20,000	20,000
Deferred tax assets	45,802	36,412	-	
Real estate assets	65,014	69,158	-	-
Other receivables	13,081	12,994	-	
Other financial assets	14,849	18,252	-	-
Other assets	60,458	43,623	-	
Total non-current assets	2,541,446	2,445,790	951,809	937,822
	2,341,440	2,443,730		557,022
Current assets				
nventories	1,270,387	1,120,839	-	-
Biological assets	130,762	108,839	-	-
Trade and other receivables	225,563	231,905	50,152	40,872
Other financial assets	5,041	2,552	2,404	2,404
Other assets	107,735	71,722	1,198	2,627
Cash at banks	264,215	320,566	100,261	137,860
Total current assets	2,003,703	1,856,423	154,015	183,763
Total assets	4,545,149	4,302,213	1,105,824	1,121,585
EQUITY AND LIABILITIES				
Equity				
Share capital	1,059,882	1,059,882	1,059,882	1,059,882
Treasury shares	(12,307)	(14,125)	(12,307)	(14,125)
Retained earnings	735,100	709,272	72,464	84,116
Other reserves	(164,519)	(157,676)	(18,174)	(16,082)
Translation reserve	(271,573)	(170,381)		
Equity attributable to owners of the parent	1,346,583	1,426,972	1,101,865	1,113,791
Non-controlling interests	694,673	719,480	-	-
Total equity	2,041,256	2,146,452	1,101,865	1,113,791
Non-current liabilities				
Defined benefit plan liabilities	85,128	88,643	-	-
Deferred tax liabilities	4,229	5,987	-	-
Other payables	14,350	15,609	598	320
Loans and borrowings	793,272	735,109	-	-
Lease liabilities	312,073	263,260	147	529
Other financial liabilities	387	1,249	-	-
Other liabilities	3,694	4,353	-	-
Total non-current liabilities	1,213,133	1,114,210	745	849
Current liabilities				
Income tax payable	16,315	22,537	8	192
Trade and other payables	452,555	403,143	2,739	6,270
Loans and borrowings	785,817	573,787	-	-
Lease liabilities	21,532	24,390	467	483
Other financial liabilities	-	152	-	-
Other liabilities	14,541	17,542		
Fotal current liabilities	1,290,760	1,041,551	3,214	6,945
Total liabilities	2,503,893	2,155,761	3,959	7,794
Total equity and liabilities	4,545,149	4,302,213	1,105,824	1,121,585

(Registration Number: 200819599W)

Total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

	<u>As at 30/9/2022</u>	<u>As at 31/12/2021</u>
Total number of issued shares excluding treasury shares	2,043,717,820	2,040,800,520

Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

	Jan - Sep		
	2022	2021	
	US Cents	US Cents	
Earnings per share for the period			
(a) Based on weighted average number of ordinary shares in issue	2.27	5.58	
(b) Based on a fully diluted basis	2.27	5.58	
Weighted Average Number of Ordinary Shares	2,042,625,144	2,039,567,194	

Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the current financial period reported on and immediately preceding financial year.

	Group		Company	
	As at 30/9/2022	As at 31/12/2021	As at 30/9/2022	As at 31/12/2021
Net asset value per ordinary share				
- in US\$	0.66	0.70	0.54	0.55
- in S\$	0.94	0.95	0.77	0.74

Net asset value per ordinary share is based on the issued share capital excluding treasury shares of the Company at the end of the financial period.